Eli Lilly partners with Creyon Bio in $13M upfront deal, potential $1B+ milestone payments. CEO Serge Messerlian leads ...

Pharmaceutical company Eli Lilly announced promising clinical trial results for a daily pill to treat obesity and diabetes, a considerable advantage over other GLP-1-based weight-loss drugs that have ...

Eli Lilly has requested Europe's medicines regulator to re-examine its opinion on the company's Alzheimer's drug, the agency ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Eli Lilly LLY underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ratings, offering a ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares closed yesterday at $726.24.